Results 171 to 180 of about 51,995 (213)
Glucagon-Like Peptide-1 Receptor Agonists and Pay-Per-Click Direct-to-Consumer Advertising.
JAMA Netw OpenEisenkraft Klein D +2 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Interventional Pharmacoeconomics
The Cancer Journal, 2020Abstract The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-
Daniel A, Goldstein +5 more
openaire +2 more sources
Drugs & Aging, 2009
The aging of the general population in industrialized countries has brought to public attention the increasing incidence of age-related clinical conditions, because the long-term impact of diseases on functional status and on costs are greater in older people than in any other age group.
Bustacchini, S. +6 more
openaire +3 more sources
The aging of the general population in industrialized countries has brought to public attention the increasing incidence of age-related clinical conditions, because the long-term impact of diseases on functional status and on costs are greater in older people than in any other age group.
Bustacchini, S. +6 more
openaire +3 more sources
Current Opinion in Gastroenterology, 1996
Eradication of Helicobacter pylori offers the potential of cost savings in combination with better outcomes over intermittent or maintenance therapy of duodenal ulcer disease. Treatment regimes that give a higher eradication rate are cost-effective despite higher costs.
Deltenre, Michel Arthur, Jönsson, Bengt
openaire +1 more source
Eradication of Helicobacter pylori offers the potential of cost savings in combination with better outcomes over intermittent or maintenance therapy of duodenal ulcer disease. Treatment regimes that give a higher eradication rate are cost-effective despite higher costs.
Deltenre, Michel Arthur, Jönsson, Bengt
openaire +1 more source
2018
Although pharmacoeconomic justifications often examine dollars spent or lives saved, the implications for the health of communities are equally important. Given the significant and growing cost of health care and medications, decision-makers face the difficult dilemma of choosing how best to optimize resources efficiently and effectively (relating to ...
Scott K Griggs, Peter Hurd
+4 more sources
Although pharmacoeconomic justifications often examine dollars spent or lives saved, the implications for the health of communities are equally important. Given the significant and growing cost of health care and medications, decision-makers face the difficult dilemma of choosing how best to optimize resources efficiently and effectively (relating to ...
Scott K Griggs, Peter Hurd
+4 more sources
Pharmacoeconomic considerations
American Journal of Health-System Pharmacy, 2003Pharmacoeconomic analyses can be readily applied to the study of venous thromboembolism (VTE) in the orthopedic postsurgical setting. The cost of VTE to the health care system and a cost-effectiveness trial that utilized a factor Xa inhibitor for VTE prophylaxis are discussed.
openaire +2 more sources
Pharmacy World & Science, 2003
Efficacy and safety are crucial considerations in judging drugs, for example, whether or not to include them in a local formulary. More and more, pharmacoeconomic aspects are becoming of additional importance. How should we interpret such pharmacoeconomic studies?
openaire +3 more sources
Efficacy and safety are crucial considerations in judging drugs, for example, whether or not to include them in a local formulary. More and more, pharmacoeconomic aspects are becoming of additional importance. How should we interpret such pharmacoeconomic studies?
openaire +3 more sources
2016
Introduction to Pharmacoeconomics, W. F. McGhan Decision Modeling Techniques, M. S. Roberts and K. J. Smith Cost of Illness, R. J. G. Arnold Markov Modeling in Decision Analysis, J. R. Beck Retrospective Database Analysis, R. J. G. Arnold and S. Balu What is Cost-Minimization Analysis?, A. Haycox Cost-Effectiveness Analysis, K. J. Smith and M.
openaire +2 more sources
Introduction to Pharmacoeconomics, W. F. McGhan Decision Modeling Techniques, M. S. Roberts and K. J. Smith Cost of Illness, R. J. G. Arnold Markov Modeling in Decision Analysis, J. R. Beck Retrospective Database Analysis, R. J. G. Arnold and S. Balu What is Cost-Minimization Analysis?, A. Haycox Cost-Effectiveness Analysis, K. J. Smith and M.
openaire +2 more sources
British journal of clinical pharmacology, 2012
U predavanju je dana definicija farmakoekonomike, vrste analiza, te primjena u praksi.
openaire +2 more sources
U predavanju je dana definicija farmakoekonomike, vrste analiza, te primjena u praksi.
openaire +2 more sources
The National medical journal of India, 2004
Pharmacoeconomics focuses on the costs and benefits of drug therapy and pharmacoeconomic evaluations provide a basis for resource allocation and utilization. It is increasingly becoming important for health policy decision-making. A pharmacoeconomic evaluation may be conducted as an economic assessment incorporated into clinical trials.
Jaya, Ahuja +3 more
openaire +1 more source
Pharmacoeconomics focuses on the costs and benefits of drug therapy and pharmacoeconomic evaluations provide a basis for resource allocation and utilization. It is increasingly becoming important for health policy decision-making. A pharmacoeconomic evaluation may be conducted as an economic assessment incorporated into clinical trials.
Jaya, Ahuja +3 more
openaire +1 more source